Quantinno Capital Management’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$50M Buy
264,383
+29,289
+12% +$5.51M 0.06% 389
2026
Q1
$46.2M Buy
235,094
+46,537
+25% +$8.97M 0.08% 297
2025
Q4
$34.7M Buy
188,557
+39,816
+27% +$6.98M 0.07% 321
2025
Q3
$22.8M Buy
148,741
+40,293
+37% +$6.1M 0.06% 372
2025
Q2
$15.2M Buy
108,448
+27,924
+35% +$3.91M 0.07% 355
2025
Q1
$11.8M Buy
80,524
+22,974
+40% +$3.32M 0.08% 306
2024
Q4
$7.54M Sell
57,550
-12,748
-18% -$1.78M 0.07% 303
2024
Q3
$11M Buy
70,298
+10,251
+17% +$1.65M 0.14% 117
2024
Q2
$9.37M Buy
60,047
+33,085
+123% +$4.98M 0.17% 91
2024
Q1
$3.65M Sell
26,962
-12,596
-32% -$1.67M 0.08% 295
2023
Q4
$5.33M Buy
39,558
+18,280
+86% +$2.38M 0.19% 92
2023
Q3
$2.88M Buy
21,278
+10,090
+90% +$1.38M 0.13% 182
2023
Q2
$1.6M Buy
11,188
+1,830
+20% +$269K 0.09% 280
2023
Q1
$1.3M Buy
9,358
+1,534
+20% +$206K 0.09% 303
2022
Q4
$1.06M Buy
+7,824
New +$981K 0.08% 335
2022
Q3
Sell
-1,609
Closed -$213K 613
2022
Q2
$213K Buy
+1,609
New +$211K 0.03% 553

Other funds holding AZN

Quantinno Capital Management's AZN Position: Q2 2026 in Review

Quantinno Capital Management increased its AstraZeneca (AZN) stake by 12% in Q2 2026, buying an estimated $5.51M and bringing the position to 264,383 shares worth $50M. The position accounts for 0.06% of the portfolio, ranked #389.

Quantinno Capital Management first reported a position in AZN in Q2 2022 and has held it in 16 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Quantinno Capital Management held 264,383 shares of AstraZeneca worth $50M as of Q2 2026.
  • Quantinno Capital Management bought 29,289 AstraZeneca shares in Q2 2026, an estimated $5.51M.
  • AstraZeneca made up 0.06% of Quantinno Capital Management's portfolio in Q2 2026, its #389 holding.
  • Quantinno Capital Management first reported a position in AstraZeneca in Q2 2022 and has held it in 16 quarters since.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.